EcoDrugPlus

Calcium Voltage-Gated Channel Subunit Alpha1 E

Ensembl ID : ENSPNAG00000014063
Gene Symbol: CACNA1E
2 Cross references
142 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 G

Ensembl ID : ENSPNAG00000008398
Gene Symbol: CACNA1G
3 Cross references
196 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 H

Ensembl ID : ENSPNAG00000010987
Gene Symbol: CACNA1H
3 Cross references
208 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 S

Ensembl ID : ENSPNAG00000001856
Gene Symbol: CACNA1S
3 Cross references
194 Possible Orthologues:

Cannabinoid Receptor 1

Ensembl ID : ENSPNAG00000013717
Gene Symbol: CNR1
3 Cross references
150 Possible Orthologues:

Cannabinoid Receptor 1-Like

Ensembl ID : ENSPNAG00000018587
Gene Symbol: LOC108441243
3 Cross references
191 Possible Orthologues:

Carbonic Anhydrase 12

Ensembl ID : ENSPNAG00000002555
Gene Symbol: CA12
3 Cross references
214 Possible Orthologues:

Carbonic Anhydrase 14

Ensembl ID : ENSPNAG00000001753
Gene Symbol: CA14
3 Cross references
208 Possible Orthologues:

Carbonic Anhydrase 4-Like

Ensembl ID : ENSPNAG00000020002
Gene Symbol: LOC108444141
3 Cross references
211 Possible Orthologues:

Carbonic Anhydrase 4-Like

Ensembl ID : ENSPNAG00000014885
Gene Symbol: LOC108427909
3 Cross references
79 Possible Orthologues:

Carbonic Anhydrase 5a

Ensembl ID : ENSPNAG00000011404
Gene Symbol: CA5A
3 Cross references
231 Possible Orthologues:

Carbonic Anhydrase 6

Ensembl ID : ENSPNAG00000019716
Gene Symbol: CA6
3 Cross references
219 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).